Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.
Código da empresaGRAL
Nome da EmpresaGrail Inc
Data de listagemJun 12, 2024
Fundado em2020
CEOMr. Robert (Bob) Ragusa
Número de funcionários1000
Tipo de títulosOrdinary Share
Fim do ano fiscalJun 12
Endereço1525 O'brien Drive
CidadeMENLO PARK
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal94025
Telefone18336942553
Sitehttps://grail.com/
Código da empresaGRAL
Data de listagemJun 12, 2024
Fundado em2020
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.

Sem dados